OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
November 19 2009 - 10:49AM
Business Wire
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it
will host a live webcast of its R&D Analyst Day on Thursday,
December 3, 2009 at 12:30 p.m. Eastern Time. The webcast will be
hosted by Colin Goddard, Ph.D., Chief Executive Officer, and
members of OSI’s management team. The Company will discuss the
status of its oncology and diabetes/obesity research and
development programs, including its Tarceva® (erlotinib) program,
and will also provide a brief financial overview. The webcast is
expected to last approximately three hours.
To access the webcast live via the Internet, please log on to
www.osip.com approximately 15 minutes before the start of
the event to allow for any software downloads that may be
necessary. Following the webcast, an archive will be available at
the same address until approximately December 31, 2010.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality, novel and differentiated targeted medicines designed
to extend life and improve the quality of life for patients with
cancer and diabetes/obesity. For additional information about OSI,
please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, OSI's and its collaborators'
abilities to effectively market and sell Tarceva and to expand the
approved indications for Tarceva, OSI’s ability to protect its
intellectual property rights, safety concerns regarding Tarceva,
competition to Tarceva and OSI’s drug candidates from other
biotechnology and pharmaceutical companies, the completion of
clinical trials, the effects of FDA and other governmental
regulation, including pricing controls, OSI's ability to
successfully develop and commercialize drug candidates, and other
factors described in OSI Pharmaceuticals' filings with the
Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024